Cognision

Executive Summary

Cognision, a Boston-based digital health company founded in 2018, is pioneering AI-driven platforms and digital biomarkers to objectively assess cognitive health. Its technology focuses on physiological measurements for evaluating disorders such as concussion and dementia, addressing the critical need for objective, scalable diagnostic tools. By targeting healthcare professionals, pharmaceutical clinical trials, and academic researchers, Cognision aims to improve the accuracy and efficiency of cognitive assessments, potentially reducing misdiagnosis and enabling earlier intervention. The company's approach leverages AI to extract insights from physiological data, offering a non-invasive, repeatable solution that could transform how cognitive conditions are monitored and treated. Despite its innovative platform, Cognision operates in a competitive and regulatory-intensive space. The company has not publicly disclosed funding rounds or regulatory milestones, suggesting an early-stage profile with limited commercial traction. However, its focus on digital biomarkers aligns with growing interest from pharma and tech sectors. Success will depend on achieving regulatory clearances, establishing clinical validation, and forming strategic partnerships. With the global cognitive assessment market expanding, Cognision has the potential to capture niche applications in sports concussion and dementia screening, though execution risks remain.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for concussion assessment platform40% success
• Q1 2027Partnership with a top-10 pharmaceutical company for Alzheimer's trial cognitive monitoring30% success
• Q2 2026Series A funding round of $10M+ led by healthcare VC50% success